Navigation Links
Sanofi-aventis Delivers 2008 Results Above Guidance
Date:2/11/2009

07 and 2008

(5) Excluding net sales of Ambien IR(R) in the United States in Q1 2007 and Q1 2008

2008 fourth-quarter financial results

Adjusted income statement excluding selected items(1)

Sanofi-aventis generated fourth-quarter net sales of EUR 7,089 million, a rise of 3.6% on a comparable basis. The appreciation of the U.S. dollar against the euro meant that exchange rate movements had a favorable effect of 1.1 points, despite the impact of other currencies. Changes in Group structure had an unfavorable effect of 2.1 points, and included the discontinuation of commercialization of Copaxone(R) in the United States and Canada by sanofi-aventis in accordance with the agreements signed with Teva. On a reported basis, net sales rose by 2.6%.

Gross profit was up 5.2% at EUR 5,529 million. Other revenues increased by 18.4%, benefiting from the impact of the rising dollar on royalties received on sales of Plavix(R) and Avapro(R) in the United States. The ratio of cost of sales to net sales improved by 1.2 points to 27.2%, reflecting to favorable foreign exchange effects and the discontinuation of commercialization of Copaxone(R) in North America.

Research and development expenses were EUR 1,306 million, a rise of 2.8% (1.3% at constant exchange rates), and include the full cost of discontinuing trials on Acomplia(R) (EUR 41 million). Selling and general expenses fell by 2.6% (-4.6% at constant exchange rates) to EUR 1,945 million. The ratio of selling and general expenses to net sales improved by 1.5 points to 27.4%, reflecting our ongoing cost adaptation measures

Other current operating income and expenses showed a net expense of EUR 24 million, against net income of EUR 15 million in the comparable period of 2007. This item includes an improvement in net income from alliances (primarily
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care
2. Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care
3. Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
4. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
5. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
6. Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1):
7. Sanofi-aventis Teams With HHS Quality Agency to Distribute Consumer Health Materials
8. Sanofi-aventis Named One of Best Employers for Healthy Lifestyles by National Business Group on Health
9. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
10. TechTeam Global Will Provide Multilingual EDC Support Services for sanofi-aventis recherche & developpement
11. Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... New York, NY (PRWEB) November 22, 2014 ... Australia’s Therapeutics Goods Administration (TGA) approved it for ... Glutathione was approved and listed within the Therapeutic ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione ... Chem, a biotech specialist that sources and imports ...
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 ... about the pain caused by the machine," said an ... injury, she had to go back a second time ... my invention idea." , She developed the patent-pending MAMO ... for breast cancer. The design saves the patient from ...
(Date:11/22/2014)... Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) that ... developed Type 2 diabetes due to its use continue ... underway in U.S. District Court, District of South Carolina, ... litigation will convene its next Status Conference on December ... Counsel for Plaintiffs and Defendants to meet and confer, ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 The Sports ... Roy Baroff to its team of conflict resolution ... soccer player, coach, and referee. He has over 30 years ... and beyond. , “I'm very excited to connect with SCI ... sports related interests to a program with a complete sports ...
(Date:11/22/2014)... 2014 Wright & Schulte LLC reports ... have been scheduled between October 2016 and April ... Illinois. U.S. District Judge Matthew F. Kennelly, who is ... Order (CMO) on November 6, 2014 that outlined the ... submit documents and other activities in preparation for the ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
... ‘Pneumonic plague’ is responsible for killing 100 people in eastern ... it has conducted. The authorities from WHO have said that ... also explained that the control measures have been hard to ... ,The outbreak had reportedly begun in mid-May. DR ...
... lives and affected 20,000 people in West Bengal's Dooars area ... West Bengal Assembly today. // ,Of the 20,000 ... malignant malaria, Das said during mention hour., ,Stating that ... it was far from adequate. Besides, there was no hospital ...
... Cadet Corps will soon sign an MoU with UN to ... in India, Director General of NCC M C Bhandari said ... the HIV infected that there were medicines for their treatment ... be ostracised, he told reporters here., ,Another MoU on ...
... distinct response of titillation when a person is exposed to ... University School of Medicine in St. Louis gauged the brainwave ... color slides, describing various scenes, the gamut ranging from water ... ,What they found may seem like a "no ...
... pancreatic surgery during the last 35 years at Johns ... J. Yeo, M.D., Samuel D. Gross Professor and chair ... University and Thomas Jefferson University Hospital in Philadelphia and ... that contrary to what many both in and out ...
... by the Mayo Clinic has revealed that acupuncture ... is a disorder considered disabling by many, and ... symptoms such as fatigue, joint stiffness and sleep ... are only partially effective. ,Mayo’s study involved ...
Cached Medicine News:Health News:Brain’s response distinct upon exposure to erotic image 2Health News:Brain’s response distinct upon exposure to erotic image 3Health News:Pancreatic Cancer Surgery Successful in 80-Year-Olds 2Health News:Pancreatic Cancer Surgery Successful in 80-Year-Olds 3Health News:Acupuncture to Relieve Fibromyalgia Symptoms 2
(Date:11/21/2014)... N.Y. , Nov. 21, 2014  Cardinal Health, ... world,s largest health care services companies, and Henry Schein, ... provider of health care products and services to office-based ... the companies have entered into a long-term strategic agreement ... product offerings to office-based medical practices.  This strategic agreement ...
(Date:11/21/2014)... N.J. , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Krakauer , Chief Executive Officer, will be presenting at the ... New York Palace Hotel in New York ... 2014 at 2:00 PM ET. In addition, Mr. Krakauer and ... available for separate one-on-one meetings during the day. ...
(Date:11/21/2014)... Nov. 20, 2014  The acceptance of two ... AAGL Global Congress demonstrates continued interest in the ... provide bowel control. One of the abstracts, presented by ... Division Chief of Urogynecology and Reconstructive Pelvic Surgery ... Award for Best Written Abstract on Urogynecology/Pelvic Floor ...
Breaking Medicine Technology:Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3
... British Columbia--(BUSINESS WIRE)--Apr 3, 2007 - ... Company(TM),announced today the publication of new ... showing that Allon's product,candidate AL-108 significantly ... the hyperphosphorylation of tau protein in ...
... BASEL, Switzerland, April 3, 2007 (PRIME NEWSWIRE) ... microbiological and,pharmacokinetic profiles of Basilea's (SWX:BSLN) two ... for ceftobiprole, the first anti-MRSA broad-spectrum,cephalosporin in ... for the treatment of invasive fungal infections,yielded ...
Cached Medicine Technology:Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's,Conference 2Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's,Conference 3Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 2Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 3Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 4Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 5Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 6Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 7
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
Medicine Products: